WEE1 Inhibitor: Clinical Development

PURPOSE OF REVIEW: WEE1 inhibitor has been shown to potential chemotherapy or radiotherapy sensitivity in preclinical models, particularly in p53-mutated or deficient cancer cells although not exclusively. Here, we review the clinical development of WEE1 inhibitor in combination with chemotherapy or...

Descripción completa

Detalles Bibliográficos
Autores principales: Kong, Anthony, Mehanna, Hisham
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Evolving Therapies (RM Bukowski, Section Editor)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285350/
https://www.ncbi.nlm.nih.gov/pubmed/34269904
http://dx.doi.org/10.1007/s11912-021-01098-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285350/
https://www.ncbi.nlm.nih.gov/pubmed/34269904
http://dx.doi.org/10.1007/s11912-021-01098-8

Ejemplares similares